Introduction
Neoplastic cells reside in a complex tissue microenvironment in which numerous infiltrated and recruited host cells interact with cancer cells to contribute to tumor initiation and progression (Lorusso and Ruegg, 2008; Anton and Glod, 2009 ). These non-neoplastic cells, including (i) endothelial cells and pericytes that together form the tumor vasculature; (ii) infiltrated inflammatory cells, including macrophages and lymphocytes and (iii) fibroblasts (Fbs), which are derived from the local existing Fbs, recruited bone marrow-derived mesenchymal stem cells (MSCs) and in some cases, epithelial-mesenchymal transition (Kalluri and Neilson, 2003; Zeisberg and Kalluri, 2008; Kalluri, 2009) , constitute the tumor-associated stroma. Fbs are the major components of tumor stroma and critically involved in regulating tumor growth, metastasis and angiogenesis through secretion of soluble factors, synthesis of extracellular matrix and direct cell-cell interaction (Olumi et al., 1999; Lynch and Matrisian, 2002; Allinen et al., 2004; Bhowmick et al., 2004; Midwood et al., 2004) . Infiltrated/recruited stromal Fbs are activated in tumor tissue and are named as cancer-associated Fbs (CAFs) (Orimo and Weinberg, 2006) . CAFs have distinct biological features that distinguish them from their normal counterparts (Kalluri and Zeisberg, 2006; Orimo and Weinberg, 2006) . The importance of CAFs in tumorigenesis has been recently highlighted. For instance, CAFs can render non-tumorigenic cells to gain a permanently transformed phenotype (Hayward et al., 2001) . In addition, CAFs extracted from invasive human breast carcinomas are more capable of promoting the growth of mammary carcinoma cells and tumor angiogenesis compared with cells derived from outside of tumor masses (Orimo et al., 2005) . Moreover, CAFs can mediate resistance to antiangiogenic therapy (Crawford et al., 2009) . CAFs, thus, may represent promising therapeutic targets in the prevention and treatment of cancer. This may be particularly important to melanoma as Fbs make up a significant portion of the tumor mass.
Cutaneous melanoma is the most dangerous form of skin cancer and its incidence rate has been rising rapidly in the last several decades (Liu and Herlyn, 2005) . Unlike many other cancers, melanoma is notorious for its propensity to metastasize and for its poor response to chemotherapy and radiation. The current clinical treatment regimens, except early surgical removal of primary lesion, are, in general, ineffective. Therefore, it is necessary to develop novel, effective therapeutics to conquer melanoma.
The Notch pathway is an evolutionarily conserved signaling cascade that regulates cellular activities in a variety of cells, including Fbs (Artavanis-Tsakonas et al., 1999) . For instance, Notch pathway activation through either overexpression of the Notch1 intracellular domain (N IC ) or stabilization of N IC by ablation of Sel-10 (Fbxw7), a negative regulator of Notch signaling, resulted in cell-cycle arrest and apoptosis in mouse embryonic Fbs (Ishikawa et al., 2008) . Consistently, inhibition of Notch signaling by soluble forms of the Delta-like-1 and Jagged1 ligands was able to induce Fb growth factor receptor-dependent transformation of NIH 3T3 Fbs in vitro (Urs et al., 2008) . These studies pointed to Notch signaling having a negatively regulatory role in controlling the cellular behavior of Fbs and suggested that the cellular activity of Fbs can be regulated by manipulation of Notch signaling.
We aim to develop a novel approach to control melanoma growth and metastasis. In this study, we tested an innovative strategy to target the melanoma microenvironment by modulating stromal Fbs through manipulation of Notch signaling. We found that engineered stromal Fbs, in which the Notch pathway is constitutively activated, were able to attenuate melanoma growth and suppress tumor angiogenesis, partially through upregulating Wnt-induced secreted protein-1 (WISP-1). Our results unveil Notch signaling and its downstream functional mediator, WISP-1, as novel targets for therapeutic modulation of stromal Fbs in the treatment of melanoma. (Figure 1a) . Inhibition was more effective at higher ratios compared with that at 1:1. The 2:1 ratio appeared to be an optimal ratio as 3:1 and 5:1 did not achieve stronger inhibition. More apoptotic melanoma cells were observed in the presence of N IC -GFP/Fbs versus GFP/Fbs. Interestingly, many of the apoptotic melanoma cells were not in contact with the co-cultured N IC -GFP/Fbs, suggesting that the Fbs -mediated inhibitory effect may be cell-cell contact-independent (at least partly) and might derive from soluble factor(s) secreted from the Fbs (Figure 1b) . To investigate such a Targeting melanoma by manipulating Notch in fibroblasts H Shao et al possibility, we tested the effect of supernatants from cultured N IC -GFP/Fbs versus GFP/Fbs on the cell growth of three melanoma cells derived from radial growth phase (WM35), vertical growth phase (WM3248) and metastatic phase (1205Lu). A conditioned medium (CM) collected from N IC -GFP/Fbs or GFP/Fbs was added and cells were cultured for 18 h. As we anticipated, the CM from N IC -GFP/Fbs was able to significantly suppress the growth of all three melanoma cells ( Figure 1c ). There were no significant differences (P40.05, white bars) in terms of the responses of the three tested melanoma cells to the CM. Our results supported the notion that the inhibitory effect of N IC -engineered Fbs is mediated by soluble factor(s). Figure 3a) . Second, blood vessel density in tumor tissues was evaluated by whole-body DiI perfusion and subsequent laser-scanning confocal microscopy to image blood vessels in tumors harvested from additional Fbmelanoma cell-co-xenografted SCID mice (n ¼ 5/group). Significantly lower blood vessel density was observed in tumors co-xenografted with N IC -GFP/Fbs than in tumors co-xenografted with GFP/Fbs (Figure 3b ). These data implicated that angiogenesis was inhibited in tumors co-xenografted with N IC -GFP/Fbs.
Results

Activation of
Upregulation of WISP-1 by Notch activation in Fbs and its inhibitory role in melanoma cell growth
The results from our in vitro study described above suggested that the inhibitory effect of N IC -engineered Fbs on melanoma cell growth is mediated, at least in part, through soluble factor(s) secreted by the Fbs. In an independent study aimed to identify targets of Notch signaling in Fbs, an elevated WISP-1 mRNA level was noted in N (Figure 4a ). To explore the potential role of WISP-1 in modulating melanoma cell behavior, recombinant WISP-1 protein was tested for its effect on 1205Lu melanoma cell growth and migration in vitro. Supplementation of ghWISP-1 protein (10 ng/ml) in the culture medium was able to partially, yet significantly, inhibit cell proliferation ( Figure 4b ). A higher dosage (200 ng/ml) of WISP-1did not further enhance its inhibitory effect, indicating that 10 ng/ml reaches a saturated concentration. By contrast, the ghWISP-1 protein did not alter 1205Lu cell migration compared with the bovine serum albumin control ( Figure 4c ). It is noteworthy that not all melanoma cells are sensitive to ghWISP-1. Of four tested melanoma cells, Sbcl2 did not respond to ghWISP-1 in cell growth ( Figure 4d ). The underlying mechanism requires future study.
As WISP-1 is inhibitory to melanoma cell proliferation, proliferating melanoma cells should not produce high levels of WISP-1. As anticipated, the three melanoma cell lines tested in our study expressed marginal levels of WISP-1 (Figure 4e ). Moreover, expression of WISP-1 in skin melanoma lesions from three patients was undetectable (Figure 4f ). Collectively, our results showed that constitutive Notch activation induces the expression of WISP-1 in Fbs, and WISP-1 has an inhibitory role in melanoma cell growth.
WISP-1 is highly expressed in inactivated Fbs but modestly in melanoma-activated Fbs As WISP-1 suppresses melanoma cell growth, melanoma-associated Fbs should not produce WISP-1 (or its production is kept at a fairly low level below the threshold required for achieving biological activity). To clarify such a possibility, expression of WISP-1 in inactivated versus melanoma-activated Fbs was examined. First, given that tumor cells activate Fbs Targeting melanoma by manipulating Notch in fibroblasts H Shao et al largely through tumor cell-secreted factors, Fbs precultured in serum-free basal medium overnight were restimulated by a CM of 1205Lu versus plain medium. After 24 h, Fbs were tested for WISP-1 expression by immunoblotting. As anticipated, a downregulation (54%) of WISP-1 in Fbs treated with CM of 1205Lu was observed (Figure 5a ), suggesting that production of WISP-1 is inhibited in 'melanoma-activated Fbs'. Second, human skin melanoma tissues were examined to detect WISP-1 expression in tumor and adjacent dermal tissue where normal, quiescent Fbs predominantly reside. Tissue sections were immunostained with anti-vimentin (fluorescein isothiocyanate-conjugated) and anti-WISP-1 (phycoerythrin-conjugated) antibodies.
A sequential section was subjected to hematoxylin and eosin staining. Both melanoma cells and Fbs were vimentin þ . Expression of WISP-1 was almost undetectable in areas with melanoma and in the surrounding area filled with infiltrated immune cells. By contrast, strong expression of WISP-1 in adjacent dermal tissue, mainly by inactivated, quiescent Fbs (vimentin þ /WISP-1 þ , yellow), was observed (Figure 5b) . A similar pattern was observed in the melanoma tissue samples from all three patients. These results implicated that 'melanomaactivated' Fbs express little WISP-1. To further test the production of WISP-1 in inactivated/quiescent Fbs, expression of WISP-1 in serum starvation plus cell-cell contact (high confluence)-induced non-proliferating Fbs Targeting melanoma by manipulating Notch in fibroblasts H Shao et al was examined. Compared with un-starved, sub-confluent (80% confluence) proliferating Fbs, inactivated/quiescent Fbs expressed increased levels of WISP-1 (Figure 5c ). Consistently, it was observed that the Notch signaling is inhibited in 'melanoma-activated' Fbs compared with that in inactivated Fbs. Expression of Hey-1 and Hes-1 was downregulated in Fbs treated with the CM of 1205Lu cells (Figure 5d ). Overall, our data showed that WISP-1 is strongly expressed in inactivated, quiescent Fbs but modestly in melanoma-activated Fbs, and thus established a correlation between WISP-1 production and the activation status of stromal Fbs. Targeting melanoma by manipulating Notch in fibroblasts H Shao et al of the critical soluble factors in mediating the inhibitory effect of N IC -engineered Fbs on melanoma cell growth. The role of WISP-1 in melanoma growth was further examined in an Fb-melanoma co-xenograft mouse model. Cell mixtures (2.4 Â 10 6 cells) of Ctrl-shRNA/ Fbs þ 1205Lu versus Wisp-1-shRNA/Fbs þ 1205Lu at a ratio of 2:1 were co-xenografted subcutaneously on SCID mice (n ¼ 6/group). The mice were killed 4 weeks after xenograft and tumors were harvested and subjected to immunohistochemistry and immunostaining analyses. N IC -engineered stromal Fb-inhibited melanoma growth in mouse skin was relieved if upregulated expression of WISP-1 was suppressed by shRNA (melanoma cells co-xenografted with Wisp-1-shRNA/ Fbs compared with those co-xenografted with CtrlshRNA/Fbs) (Figure 6c ). Correspondingly, increased numbers of proliferating (Ki67 þ ) whereas decreased numbers of apoptotic cells were detectable in the Wisp-1-shRNA/Fbs co-xenografted tumor tissue compared with tissue co-xenografted with Ctrl-shRNA/Fbs (Figures 6d and e) . Additionally, in contrast to that observed in tumors co-xenografted with N IC -GFP/Fbs, profoundly more blood vessels (CD31 þ ) were detectable in tumors co-xenografted with Wisp-1-shRNA/Fbs (Figure 6f ). Collectively, these data showed that attenuation of Notch-upregulated WISP-1 expression in Fbs could significantly liberate the inhibitory effect of N IC -engineered stromal Fbs on melanoma growth and tumor angiogenesis. Our study, therefore, showed a critical role of WISP-1 in mediating the inhibitory effect of N IC -engineered stromal Fbs on melanoma growth.
Discussion
Cancer treatments are now being considered that focus on the tumor microenvironment as a therapeutic target, whereas studies exploring the approach to target Fbs in melanoma are limited. The current study found that (i) the positive role of stromal Fbs in fostering melanoma growth and tumor angiogenesis could be converted into a negative (tumor suppression) by constitutive activation of the Notch pathway; (ii) WISP-1 had an important role in inhibiting melanoma cell growth and (iii) the inhibitory effect of N IC -engineered Fbs on melanoma progression is mediated, at least in part, by upregulated expression of WISP-1. Our study identified Notch signaling and one of its downstream mediators, WISP-1, as novel targets for modulating the biological activity of stromal Fbs, and proposed a new paradigm for melanoma therapy through targeting the tumor microenvironment. Targeting tumor stromal Fbs 
Targeting melanoma by manipulating Notch in fibroblasts
H Shao et al includes the following advantages: (i) unlike tumor cells that are 'abnormal' (often with genetic alterations) and 'smart' (easy to gain resistance to chemo-and radiotherapies), stromal Fbs in tumor tissue are 'normal' cells and genetically more stable so they are less likely to evolve to become treatment-resistant; (ii) a part of Fbs in tumor tissue comes from bone marrow-derived MSCs; this provides a chance to design/conduct 'off-(tumor)site' or 'ex vivo' manipulation of this specific population of cells to achieve 'on-(tumor)site' effect after engineered MSCs are recruited to tumor tissue; (iii) may achieve 'double hits' effects through both antitumor and antiangiogenesis and (iv) may apply to treat different types of solid tumors in addition to melanoma. The cellular activities of Fbs are tightly controlled. In normal adult tissue, resident Fbs are maintained in a relatively quiescent state in which they are involved in slow turnover of the extracellular matrix. When tissue is undergoing tumorigenesis, local quiescent resident Fbs are stimulated and bone marrow-derived MSCs are recruited by tumor cell-derived stimulatory factors and inflammatory cytokines/chemokines. Quiescent Fbs are activated and recruited the MSCs are induced to differentiate into Fbs. Activated Fbs (also known as CAF) actively produce growth factors, cytokines/ chemokines, extracellular matrix and express a-smooth muscle actin and vimentin (Sappino et al., 1988) . The biological behaviors of Fbs can be regulated by a variety of signals. The current work shows that Notch signaling has a critical role in modulating the cellular activity of Fbs, and activation of the Notch pathway aids to convert Fbs from 'tumor promoters' to 'negative regulators'. Our observations, thus, are consistent with earlier reports (Ishikawa et al., 2008; Urs et al., 2008) highlighting Notch signaling as a negative regulator in controlling the cellular activity of Fbs, and collectively provide a theoretic basis for practically targeting Notch signaling as a unique approach to modulate the functional phenotype of stromal Fbs in tumor tissue. On the other hand, Notch signaling is involved in regulating cellular behavior in a variety of cells. The biological outcome of Notch pathway activation depends upon the cell type and tissue context. Dysregulation of the Notch pathway has been associated with a wide range of cancers. The Notch pathway could be either oncogenic or tumor suppressive (Yin et al., 2010) . We have previously shown that Notch activation in melanoma has a critical role in driving tumor progression (Balint et al., 2005; Liu et al., 2006) , and defined an oncogenic role for Notch signaling in melanocytic transformation (Pinnix et al., 2009) . Additionally, Notch and Notch ligands, for example, Delta-like 4 (Dll4), are robustly expressed in tumor endothelial cells in comparison with that in neighboring, normal tissue vessels (Mailhos et al., 2001) , and vascular endothelial growth factor, which can be predominately produced by tumor cells, can induce endothelial cells to express Notch1 and Dll4 (Liu et al., 2003; Noguera-Troise et al., 2006; Ridgway et al., 2006) . In fact, blockade of Dll4-Notch signaling is an emerging therapeutic approach to inhibit tumor angiogenesis (Thurston et al., 2007; Dufraine et al., 2008; Yin et al., 2010 ). It appears that both the status of Notch signaling and outcomes of Notch pathway activation in terms of cellular behavior are opposite in melanoma and Fbs. In melanoma tissue, seemingly, the Notch pathway is 'ON' in melanoma cells whereas 'OFF' in CAFs. It is unclear how Notch signaling is differentially regulated in two types of neighbor cells in a single microenvironment. It is also unclear whether Notch/ligands participate in the cellcell communication between Fbs-melanoma cells and Fb--endothelial cells. Whether the inhibitory effect of N IC -engineered stromal Fbs on tumor angiogenesis is a direct action of Fbs to endothelial cells or a melanoma cell-dependent indirect consequence remains undefined. Nonetheless, from the point of view of therapeutic practice, specifically activating Notch signaling in CAFs, while not simultaneously stimulating the Notch pathway in melanoma cells and tumor endothelial cells, will be a key solution. Our findings of WISP-1 as a functional mediator of Notch signaling in suppressing melanoma proliferation provide an additional target to control melanoma growth as a soluble factor is much easier to be administered.
WISP-1, also known as CCN4, was initially identified as a Wnt1-responsive target (Pennica et al., 1998) , and belongs to the CCN family, which includes the connective tissue growth factor, cysteine-rich-61 (CYR61) and nephroblastoma overexpressed (NOV) (Sakamoto et al., 2002) . Potential involvements of WISP-1 in several cancers have been reported (Soon et al., 2003; Chen et al., 2007; Davies et al., 2007) , whereas its role in melanoma remains unexplored. We sought to investigate the biological function of WISP-1 in melanoma. Secretion of WISP-1 by N IC -engineered Fbs attenuates the ability of melanoma cells to proliferate, although other unidentified factors regulated by Notch signaling may cooperate with WISP-1 as supplement of WISP-1 only partially inhibits melanoma cell proliferation compared with the CM from N IC -GFP/ Fbs. In vivo WISP-1-shRNA treatment achieves more profoundly reversing effect compared with in vitro ghWISP-1 treatment in the inhibition of melanoma cell growth. One possibility is that WISP-1 can simultaneously target tumor cells and stromal cells, such as CAFs, in vivo, thereby achieving a stronger inhibitory effect. Alternatively, there is a difference between the recombinant protein and the endogenous one. Indeed, it was reported that a naturally occurring variant of WISP-1 called WISP-1v lacks domain-II, which bears significant homology to von Willebrand factor CII and contains a putative transforming growth factor-b/BMPbinding site. WISP1v transfectants enhanced the invasive phenotype of co-cultured gastric carcinoma cells, whereas wild-type WISP1 had no such potential (Tanaka et al., 2001) . Moreover, as melanoma is a notoriously heterogeneous tumor, the sensitivity of individual melanoma cell to WISP-1 may not be identical as not all melanoma cells we tested respond to ghWISP-1 treatment. While the molecular mechanisms by which WISP-1 inhibits melanoma growth and tumor angiogenesis remain unexplored, our study locates WISP-1 as a downstream target gene of Notch signaling, and unveils WISP-1 as one of the Notchregulated, stromal Fb-secreted paracrine factors in mediating stroma-melanoma interaction, and highlighted WISP-1 as an effective therapeutic target in melanoma. WISP-1 may serve as a potential CAF-based therapeutic tool for melanoma treatment.
Materials and methods
Cells and cell culture
Primary human dermal Fbs (FF2441) were isolated from neonatal foreskin (Meier et al., 2000) and cultured in Dulbecco's Modified Eagle's Medium supplemented with 20 mM L-glutamine, 8 mM HEPES and 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). Human melanoma cell lines (1205Lu, WM35, WM3248, Sbcl2, WM278 and WM3899) derived from different progression stages were cultured in 2% FBS-W489 medium as described by Balint et al. (2005) . All cell culture media were purchased from Invitrogen (Carlsbad, CA, USA) unless indicated.
Co-culture of melanoma cells-Fbs
Melanoma cells, 1205Lu, were pre-labeled 1 day before the coculture experiment using red fluorescence nano-particles (Qtracker 655 Cell Labeling kit; Invitrogen) by following the manufacturer's protocol. N IC -GFP/Fbs or GFP/Fbs were mixed with pre-labeled 1205Lu at a 1:1 or 2:1 ratio, and a total of 1.2 Â 10 5 cells per well were plated into six-well plates. The cells were cultured in a serum-free W489 and Dulbecco's Modified Eagle's Medium mixture (1:1). After 2 days, the cells were detached, counted and analyzed by flow cytometry (FACSAria II; BD Biosciences, Rockville, MD, USA).
Cell proliferation and migration assay
The cell proliferation assay was conducted using the WST cell proliferation kit (BioVision, Mountain View, CA, USA) according to the manufacturer's protocol. To test the effect of ghWISP-1 and CM of Fbs on melanoma cell growth, Fbs at 80% confluence were cultured with serum-free Dulbecco's Modified Eagle's Medium for 2 days. CMs were collected, filtrated and applied to culture (100ml/well) melanoma cells, which were pre-plated on 96-well plates (2.5 Â 10 3 cells per well), and pre-washed with phosphate-buffered saline three times before exposure to CM or ghWISP-1 (R&D Systems, Minneapolis, MN, USA). The cells were cultured with CM or ghWISP-1 overnight and 10 ml of WST solution was added to each well. The plates were incubated for 4 h at 37 1C. Absorbance was read at 450 nm. To test melanoma cell migration, 10 4 GFP/ lentivirus-transduced 1205Lu cells were plated in the upper chamber of a 24-transwell plate (insert has 8.0-mm pores; BD Biosciences; cat. no. 351152) and cultured in basal tumor medium (serum-free, insulin-free), whereas the same basal medium with (ghWISP-1: 200 ng/ml) or without (bovine serum albumin: 200 ng/ml) ghWISP-1 was added to the lower chamber. Transmigrated melanoma cells from the upper to the lower chamber were quantified by detection of GFP signals on the reverse-side of insert after 12-h culture at 37 1C.
Immunoblotting, immunostaining and immunohistochemistry Immunoblotting was performed as described by Liu et al. (2003) . Membranes were probed with antibodies to Notch1 (ab27526; Abcam, Cambridge, MA, USA), WISP-1 (sc-25441; Santa Cruz Inc, Santa Cruz, CA, USA), Hey-1 (GTX42614; GeneTex, Irvine, CA, USA), Hes-1 (ab71559; Abcam) and b-actin (AC-15; Sigma-Aldrich, St Louis, MO, USA), followed by a horseradish peroxidase-conjugated secondary antibody (sc-2313; Santa Cruz) and subjected to enhanced chemiluminescence using the Western Blotting Luminol Reagent (sc-2048; Santa Cruz). The membranes were stripped and re-blotted as required in individual experiments. For quantification, X-ray films were scanned and analyzed using the NIH ImageJ software (Bethesda, MD, USA).
Immunostaining and immunohistochemistry were performed as described by Liu et al. (2010) . De-identified slides, including three different human melanoma specimens, were obtained under a non-human research protocol approved by the institutional review board at the University of Miami. De-paraffinzed tissue sections were blocked using a blocking solution (DakoCytomation, no. X0909; Dako, Carpinteria, CA, USA). Anti-Ki67, anti-GFP, anti-Vimentin (ab15580, ab6658, ab8978; Abcam) and anti-WISP-1 (sc-25441) were applied overnight at 4 1C and followed by the corresponding secondary antibodies. For anti-CD31 (ab56299; Abcam) immunohistochemistry, the ABC system was used. After addition of the diaminobenzidine chromogen, slides were counterstained with methyl green. For immunostaining, nuclei were stained using 4 0 ,6-diamidino-2-phenylindole (D21490; Invitrogen).
Apoptosis assay
Apoptotic cells in the tumor tissues were detected using the ApopTag Plus Peroxidase In Situ Apoptosis kit (Millipore Corporation, Billerica, MA, USA) according to the manufacturer's protocol. Paraffin-embedded tumor tissue sections measuring 5 mm were examined and nuclei were counterstained using methyl green.
Recombinant lentiviruses and shRNA/lentivirus-mediated knockdown of WISP-1 The methods for generation of GFP/lentiviruses and N IC -GFP/ lentiviruses have been described previously (Balint et al., 2005) . Pseudotyped lentivirus was produced by co-transfecting 293T cells with three plasmids as described by Balint et al. (2005) . The lentiviruses collected 48 h after transfection showed titers of approximately 10 7 transducing units per ml in NIH/3T3 cells. The WISP1-shRNA/lentivirus (sc-39335-V) and nontargeting Ctrl-shRNA/lentivirus (sc-108080) were purchased from Santa Cruz. Cells were transduced with lentiviruses for 6 h at multiplicity of infection of 5 in the presence of 4 mg/ml polybrene (Sigma-Aldrich). The cells were then washed, cultured with a regular complete medium for two additional days and analyzed for protein expression by immunoblotting or pooled for subsequent analysis as indicated in individual experiments.
Mouse xenograft model
All animal experiments were conducted with approval from the University of Miami Institutional Animal Care and Use Committee. Melanoma cells were mixed with Fbs at a ratio of 1:2 and injected subcutaneously on the dorsal site of SCID mice (Charles River, Wilmington, MA, USA) at age 8-10 weeks. A cell mixture of 2.4 Â 10 6 cells was injected per mouse. Tumor size was recorded by weekly photography. The mice were killed at week 4 after xenografting.
Blood vessel perfusion and laser-scanning confocal microscopy To assess tumor angiogenesis, blood vessels were directly labeled in anesthetized mice by live perfusion using a specially formulated aqueous solution (7 ml per mouse) containing DiI (D-282; Invitrogen), which was administered by direct intracardiac injection prior to killing the animals, as previously reported by Li et al. (2008) and Liu et al. (2010) . A 7-ml volume of fixative (4% paraformaldehyde) was injected following DiI perfusion and the entire tumor tissue was harvested. The vascular network was visualized by laserscanning confocal microscopy, by scanning the entire tumor tissue to a depth of 200 mm by (Vibratome, T1000S; Leica Microsystems, Buffalo Grove, IL, USA). Vessel density was quantified by assessing the total number of DiI-labeled (red) vessels normalized to the entire scanned tumor area using the ImageJ software.
Statistical analyses
Statistical analysis of differences was performed by two-tail Student's t-test. The data were analyzed using Microsoft Excel (Microsoft Corp., Redmond, WA, USA). The data are expressed as the mean±s.d. The values are considered statistically significant when Po0.05.
